Jubilant Pharmova Limited Cash Flow Conversion Efficiency
Jubilant Pharmova Limited cash flow conversion efficiency. Based on the latest financial reports, Jubilant Pharmova Limited (JUBLPHARMA) has a cash flow conversion efficiency ratio of 0.056x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs3.69 Billion ≈ $39.91 Million USD) by net assets (Rs65.72 Billion ≈ $710.70 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see JUBLPHARMA stock market capitalisation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Jubilant Pharmova Limited (2004–2025)
Cash flow conversion efficiency of Jubilant Pharmova Limited from 2004 to 2025. This chart illustrates how Jubilant Pharmova Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Jubilant Pharmova Limited (JUBLPHARMA) stock price for real-time trading data and today's change.
Jubilant Pharmova Limited Cash Flow Conversion Ratio Explained
Jubilant Pharmova Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Jubilant Pharmova Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jubilant Pharmova Limited ranked by their cash flow conversion efficiency. Review JUBLPHARMA free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Homeco Daily Needs REIT
AU:HDN
|
0.020x |
|
ORG Packaging Co Ltd
SHE:002701
|
0.068x |
|
A-Zenith Home Furnishings Co Ltd
SHG:603389
|
-0.265x |
|
China Nonferrous Metal Industry’s Foreign Engineering and Construction Co Ltd
SHE:000758
|
-0.124x |
|
OPmobility SE
PA:OPM
|
0.191x |
|
Guangdong Jia Yuan Technology Co Ltd
SHG:688388
|
0.006x |
|
AKSO HEALTH GR. (SPADR)/3
F:8HX
|
N/A |
|
Zhejiang CONBA Pharmaceutical Co Ltd
SHG:600572
|
0.018x |
Annual Cash Flow Conversion Efficiency for Jubilant Pharmova Limited (2004–2025)
The table below shows the annual cash flow conversion efficiency of Jubilant Pharmova Limited from 2004 to 2025. Also see JUBLPHARMA total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs62.39 Billion ≈ $674.68 Million |
Rs10.72 Billion ≈ $115.94 Million |
0.172x | -4.09% |
| 2024-03-31 | Rs54.21 Billion ≈ $586.27 Million |
Rs9.71 Billion ≈ $105.04 Million |
0.179x | +46.22% |
| 2023-03-31 | Rs53.92 Billion ≈ $583.10 Million |
Rs6.61 Billion ≈ $71.45 Million |
0.123x | -22.22% |
| 2022-03-31 | Rs53.16 Billion ≈ $574.95 Million |
Rs8.38 Billion ≈ $90.58 Million |
0.158x | -58.14% |
| 2021-03-31 | Rs47.42 Billion ≈ $512.78 Million |
Rs17.84 Billion ≈ $192.96 Million |
0.376x | +36.67% |
| 2020-03-31 | Rs56.04 Billion ≈ $606.04 Million |
Rs15.43 Billion ≈ $166.86 Million |
0.275x | +18.06% |
| 2019-03-31 | Rs48.09 Billion ≈ $520.08 Million |
Rs11.22 Billion ≈ $121.29 Million |
0.233x | -27.79% |
| 2018-03-31 | Rs40.35 Billion ≈ $436.37 Million |
Rs13.03 Billion ≈ $140.94 Million |
0.323x | -13.51% |
| 2017-03-31 | Rs33.97 Billion ≈ $367.35 Million |
Rs12.68 Billion ≈ $137.18 Million |
0.373x | -0.53% |
| 2016-03-31 | Rs29.10 Billion ≈ $314.66 Million |
Rs10.92 Billion ≈ $118.13 Million |
0.375x | +17.60% |
| 2015-03-31 | Rs24.54 Billion ≈ $265.34 Million |
Rs7.83 Billion ≈ $84.71 Million |
0.319x | +10.75% |
| 2014-03-31 | Rs27.84 Billion ≈ $301.13 Million |
Rs8.03 Billion ≈ $86.80 Million |
0.288x | -22.56% |
| 2013-03-31 | Rs26.06 Billion ≈ $281.82 Million |
Rs9.70 Billion ≈ $104.90 Million |
0.372x | +26.19% |
| 2012-03-31 | Rs23.99 Billion ≈ $259.41 Million |
Rs7.08 Billion ≈ $76.52 Million |
0.295x | +68.29% |
| 2011-03-31 | Rs22.14 Billion ≈ $239.44 Million |
Rs3.88 Billion ≈ $41.97 Million |
0.175x | -44.69% |
| 2010-03-31 | Rs22.39 Billion ≈ $242.17 Million |
Rs7.10 Billion ≈ $76.74 Million |
0.317x | -28.02% |
| 2009-03-31 | Rs12.68 Billion ≈ $137.08 Million |
Rs5.58 Billion ≈ $60.35 Million |
0.440x | +21.03% |
| 2008-03-31 | Rs12.56 Billion ≈ $135.85 Million |
Rs4.57 Billion ≈ $49.42 Million |
0.364x | +72.91% |
| 2007-03-31 | Rs9.06 Billion ≈ $98.00 Million |
Rs1.91 Billion ≈ $20.62 Million |
0.210x | +1147.30% |
| 2006-03-31 | Rs8.41 Billion ≈ $90.93 Million |
Rs141.82 Million ≈ $1.53 Million |
0.017x | -92.38% |
| 2005-03-31 | Rs5.04 Billion ≈ $54.56 Million |
Rs1.12 Billion ≈ $12.08 Million |
0.221x | -44.92% |
| 2004-03-31 | Rs2.10 Billion ≈ $22.69 Million |
Rs843.14 Million ≈ $9.12 Million |
0.402x | -- |
About Jubilant Pharmova Limited
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment o… Read more